现代仪器与医疗

多孔空心氧化铁纳米增敏剂增强射频消融的研究

PDF下载

江泽龙 , 赵昌 ^*

现代仪器与医疗 | 医学工程 2025,31(3): 24-29

收起

现代仪器与医疗 |医学工程 2025 , 31 (3) : 24 -29

多孔空心氧化铁纳米增敏剂增强射频消融的研究

全屏

[Author(id=1320388903962526085, tenantId=1146029695717560320, journalId=1319373289681944729, articleId=1320388903002030462, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1320388904033829255, tenantId=1146029695717560320, journalId=1319373289681944729, articleId=1320388903002030462, authorId=1320388903962526085, language=EN, stringName=Zelong Jiang, firstName=Zelong, middleName=null, lastName=Jiang, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Interventional Therapy, Guangxi Medical University Cancer Hospital, Nanning 530000, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1320388905677996424, tenantId=1146029695717560320, journalId=1319373289681944729, articleId=1320388903002030462, authorId=1320388903962526085, language=CN, stringName=江泽龙, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=广西医科大学附属肿瘤医院介入治疗科，南宁　530000, bio={"content":"

江泽龙，男，硕士研究生，住院医师，研究方向：肿瘤仿生药物

"}, bioImg=null, bioContent=

江泽龙，男，硕士研究生，住院医师，研究方向：肿瘤仿生药物

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1320388903765393793, tenantId=1146029695717560320, journalId=1319373289681944729, articleId=1320388903002030462, xref=null, ext=[AuthorCompanyExt(id=1320388903836696962, tenantId=1146029695717560320, journalId=1319373289681944729, articleId=1320388903002030462, companyId=1320388903765393793, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Interventional Therapy, Guangxi Medical University Cancer Hospital, Nanning 530000, China), AuthorCompanyExt(id=1320388903849279875, tenantId=1146029695717560320, journalId=1319373289681944729, articleId=1320388903002030462, companyId=1320388903765393793, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=广西医科大学附属肿瘤医院介入治疗科，南宁　530000)])]), Author(id=1320388905770271114, tenantId=1146029695717560320, journalId=1319373289681944729, articleId=1320388903002030462, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1320388905879323020, tenantId=1146029695717560320, journalId=1319373289681944729, articleId=1320388903002030462, authorId=1320388905770271114, language=EN, stringName=Chang Zhao, firstName=Chang, middleName=null, lastName=Zhao, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=^*, address=Department of Interventional Therapy, Guangxi Medical University Cancer Hospital, Nanning 530000, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1320388905979986317, tenantId=1146029695717560320, journalId=1319373289681944729, articleId=1320388903002030462, authorId=1320388905770271114, language=CN, stringName=赵昌, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=^*, address=广西医科大学附属肿瘤医院介入治疗科，南宁　530000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1320388903765393793, tenantId=1146029695717560320, journalId=1319373289681944729, articleId=1320388903002030462, xref=null, ext=[AuthorCompanyExt(id=1320388903836696962, tenantId=1146029695717560320, journalId=1319373289681944729, articleId=1320388903002030462, companyId=1320388903765393793, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Interventional Therapy, Guangxi Medical University Cancer Hospital, Nanning 530000, China), AuthorCompanyExt(id=1320388903849279875, tenantId=1146029695717560320, journalId=1319373289681944729, articleId=1320388903002030462, companyId=1320388903765393793, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=广西医科大学附属肿瘤医院介入治疗科，南宁　530000)])])]

江泽龙, 赵昌^*

作者信息

广西医科大学附属肿瘤医院介入治疗科，南宁　530000

通讯作者:

赵昌，男，博士研究生，主任医师，研究方向：肿瘤仿生药物

作者简介:

江泽龙，男，硕士研究生，住院医师，研究方向：肿瘤仿生药物

Porous hollow iron oxide nanosensitizers for enhanced radiofrequency ablation

Zelong Jiang, Chang Zhao^*

Affiliations

Department of Interventional Therapy, Guangxi Medical University Cancer Hospital, Nanning 530000, China

出版时间: 2025-06-10 doi: 10.11876/mimt202503004

文章导航

摘要

收起

目的

通过在多孔空心氧化铁纳米颗粒（hollow iron oxide nanoparticles，HION）上负载VER-155008制备纳米增敏剂（HION/VER），研究HION/VER增强射频消融对肝癌肿瘤的作用机制与效果。

方法

通过透射电镜及表面电位实验，考察多孔空心氧化铁纳米增敏剂的构建及药物负载。通过细胞生存率以及细胞活/死染色实验，考察增敏剂的体外抗肿瘤能力。通过检测细胞内活性氧（reactive oxygen species，ROS）、谷胱甘肽（glutathione，GSH）以及热休克蛋白70（heat shock protein 70，HSP70）水平，考察纳米增敏剂体外抗肿瘤机制。

结果

通过材料表征分析，多孔空心氧化铁纳米增敏剂已成功构建，粒径约为100 nm。在56.89 μg/mL和45℃条件下，HION/VER将肿瘤细胞生存率降低至50%。细胞活/死染色实验进一步证实，大量肿瘤细胞死亡，表明HION/VER具有良好的体外抗肿瘤能力。通过ROS荧光探针及GSH水平分析，ROS荧光明显增强，GSH水平下降，表明HION/VER可以通过破坏氧化还原平衡的机制来促进肿瘤铁死亡。通过HSP70免疫荧光实验分析，经过HION/VER处理后，细胞HSP70表达量明显减少，表明HION-VER通过抑制HSP70增加了肿瘤细胞对轻度射频消融的敏感性。

结论

HION/VER被肿瘤细胞内吞后，细胞摄取药物量增加，通过破坏氧化还原平衡增强铁死亡，抑制HSP70增加了肿瘤细胞对轻度射频消融的敏感性，有效提高了射频消融的效果。

关键词

射频消融 / 热休克蛋白 / 肝细胞癌 / 靶向 / 肿瘤治疗

Abstract

收起

Objective

To investigate the mechanism and effect of porous hollow iron oxide nanoparticles (HION) nanosensitizers (HION/VER) loaded with VER-155008 prepared to enhance the radiofrequency ablation on hepatocellular carcinoma tumors.

Methods

The construction of porous hollow iron oxide nanosensitizers and drug loading were investigated by transmission electron microscopy and zeta potential experiments. The in vitro anti-tumor ability of the sensitizers was examined by cell viability and cell live/dead staining experiments. The in vitro anti-tumor mechanism of the sensitizers was investigated by measuring the intracellular levels of reactive oxygen species (ROS), glutathione (GSH) and heat shock protein 70 (HSP70).

Results

Through material characterization analysis, porous hollow iron oxide nanosensitizers have been successfully constructed with a particle size of about 100 nm. HION/VER reduced tumor cell survival to 50% at 56.89 μg/mL and 45℃. Live/dead staining assay further confirmed that a large number of tumor cells died, indicating that HION/VER has good anti-tumor ability in vitro. Analysis by reactive oxygen fluorescence probe and glutathione level showed that reactive oxygen fluorescence was significantly enhanced and GSH levels decreased, indicating that HION/VER nano-sensitizer could promote iron death through the mechanism of disrupting redox balance. Analyzed by HSP70 immunofluorescence assay, the cellular HSP70 expression was significantly reduced after HION/VER treatment, indicating that the nano-sensitizer increased the sensitivity of tumor cells to mild radiofrequency ablation by inhibiting HSP70.

Conclusion

After HION/VER was endocytosed by the tumor cells, the drug uptake in the cells was increased, and the inhibition of HSP70 increased the sensitivity of the tumor cells to mild radiofrequency ablation by disrupting the redox balance to enhance the iron death, and the effect of radiofrequency ablation was achieved by effectively increasing the sensitivity of the tumor cells to mild radiofrequency ablation.

Key words

Radiofrequency ablation / Heat shock proteins / Hepatocellular carcinoma / Targeting / Tumor therapy

引用本文

江泽龙, 赵昌. 多孔空心氧化铁纳米增敏剂增强射频消融的研究. 现代仪器与医疗, 2025 , 31 (3) : 24 -29 . DOI: 10.11876/mimt202503004

Zelong Jiang, Chang Zhao. Porous hollow iron oxide nanosensitizers for enhanced radiofrequency ablation[J]. Modern Instruments & Medical Treatment, 2025 , 31 (3) : 24 -29 . DOI: 10.11876/mimt202503004

基金

收起

柳州市科技计划项目(2022SB017)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2024, 74(3): 229-263.

[2]

Deng M, Li S H, Guo R P. Recent advances in local thermal ablation therapy for hepatocellular carcinoma[J]. The American Surgeon, 2023, 89(5): 1966-1973.

[3]

Chu K F, Dupuy D E. Thermal ablation of tumours: biological mechanisms and advances in therapy[J]. Nature Reviews Cancer, 2014, 14(3): 199-208.

[4]

Wang H, Wu Z, Cui D, et al. Radiofrequency ablation of hepatocellular carcinoma: current status, challenges, and prospects[J]. Liver Research, 2023, 7(2): 108-115.

[5]

Takayama T, Hasegawa K, Izumi N, et al. Surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF Trial)[J]. Liver Cancer, 2022, 11(3): 209-218.

[6]

Hsieh C L, Peng C M, Chen C W, et al. Benefits and drawbacks of radiofrequency ablation via percutaneous or minimally invasive surgery for treating hepatocellular carcinoma[J]. World Journal of Gastrointestinal Surgery, 2024, 16(11): 3400-3407.

[7]

Reynolds A R, Furlan A, Fetzer D T, et al. Infiltrative hepatocellular carcinoma: what radiologists need to know[J]. Radiographics, 2015, 35(2): 371-386.

[8]

Lam V W, Ng K K, Chok K S, et al. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma[J]. Journal of the American College of Surgeons, 2008, 207(1): 20-29.

[9]

Hasegawa T, Takaki H, Kodama H, et al. Impact of the ablative margin on local tumor progression after radiofrequency ablation for lung metastases from colorectal carcinoma: supplementary analysis of a phase II trial (MLCSG-0802)[J]. Journal of Vascular and Interventional Radiology, 2023, 34(1): 31-37.

[10]

Bhardwaj N, Dormer J, Ahmad F, et al. Heat shock protein 70 expression following hepatic radiofrequency ablation is affected by adjacent vasculature[J]. The Journal of Surgical Research, 2012, 173(2): 249-257.

[11]

Rohde M, Daugaard M, Jensen M H, et al. Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms[J]. Genes & Development, 2005, 19(5): 570-582.

[12]

Murakami N, Kühnel A, Schmid T E, et al. Role of membrane Hsp70 in radiation sensitivity of tumor cells[J]. Radiation Oncology, 2015, 10: 149.

[13]

Chatterjee S, Burns T F. Targeting heat shock proteins in cancer: a promising therapeutic approach[J]. International Journal of Molecular Sciences, 2017, 18(9): 1978.

[14]

Liu G H, Chen T, Zhang X, et al. Small molecule inhibitors targeting the cancers[J]. MedComm, 2022, 3(4): e181.

[15]

Ali Zaidi S S, Fatima F, Ali Zaidi S A, et al. Engineering siRNA therapeutics: challenges and strategies[J]. Journal of Nanobiotechnology, 2023, 21(1): 381.

[16]

Li X, Liu Y, Ke J, et al. Enhancing radiofrequency ablation for hepatocellular carcinoma: nano-epidrug effects on immune modulation and antigenicity restoration[J]. Advanced Materials, 2024, 36(52): e2414365.

[17]

Dastgerdi N K, Dastgerdi N K, Bayraktutan H, et al. Enhancing siRNA cancer therapy: multifaceted strategies with lipid and polymer-based carrier systems[J]. International Journal of Pharmaceutics, 2024, 663: 124545.

[18]

Wang X, Yang Y, Zhang G, et al. NIR-cleavable and pH-responsive polymeric yolk-shell nanoparticles for controlled drug release[J]. Biomacromolecules, 2023, 24(5): 2009-2021.

[19]

Cao Y, Zhu X, Hossen M N, et al. Augmentation of vaccine-induced humoral and cellular immunity by a physical radiofrequency adjuvant[J]. Nat Commun, 2018, 9: 3695.

[20]

Su T, Liao J, Dai Z, et al. Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after insufficient radiofrequency ablation[J]. Oncogene, 2018, 37(26): 3514-3527.

[21]

Shuhe Y, Miroslaw K, Naoki I. Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma[J]. Hepatology, 2013, 58(5): 1667-1680.

[22]

Peng B, Ling X, Huang T, et al. HSP70 via HIF-1 α SUMOylation inhibits ferroptosis inducing lung cancer recurrence after insufficient radiofrequency ablation[J]. PloS One, 2023, 18(11): e0294263.

[23]

Ahmed M, Kumar G, Gourevitch S, et al. Radiofrequency ablation (RFA)-induced systemic tumor growth can be reduced by suppression of resultant heat shock proteins[J]. International Journal of Hyperthermia, 2018, 34(7): 934-942.

[24]

Yang Z, Zhu Y, Dong Z, et al. Tumor-killing nanoreactors fueled by tumor debris can enhance radiofrequency ablation therapy and boost antitumor immune responses[J]. Nature Communications, 2021, 12: 4299.

[25]

Wang D, Zhang M, Zhang Y, et al. Intraparticle double-scattering-decoded sonogenetics for augmenting immune checkpoint blockade and CAR-T therapy[J]. Advanced Science, 2022, 9(32): e2203106.

[26]

Zhang M, Bao S, Qiu G, et al. An magnetic-targeting nano-diagnosis and treatment platform for TNBC[J]. Breast Cancer: Targets and Therapy, 2023, 15: 101-119.

[27]

Wang D, Zhang M, Qiu G, et al. Extracellular matrix viscosity reprogramming by in situ Au bioreactor-boosted microwavegenetics disables tumor escape in CAR-T immunotherapy[J]. ACS Nano, 2023, 17(6): 5503-5516.

2025年第31卷第3期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.11876/mimt202503004

首发时间：2026-10-23
出版时间：2025-06-10

补充材料

相关文章

文章信息

作者

出版历史

基金

柳州市科技计划项目(2022SB017)

作者信息

广西医科大学附属肿瘤医院介入治疗科，南宁　530000

通讯作者:

赵昌，男，博士研究生，主任医师，研究方向：肿瘤仿生药物

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/xdyqyyl/CN/10.11876/mimt202503004

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT